Aldeyra therapeutics, inc. (ALDX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Schedule Of Restructuring And Related Costs [Table]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-9,868

-13,160

-18,715

-13,327

-15,624

-10,633

-10,812

-9,050

-8,397

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-6,954

-4,986

-5,308

-5,091

-4,651

-4,778

-4,302

-4,967

-4,355

-3,365

-2,232

-2,136

-2,444

-2,009

-1,135

401

Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development

-

67

-47

-49

6,597

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred taxes

-

0

0

0

-1,309

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,953

1,948

2,152

2,094

1,886

1,017

1,273

984

868

592

659

605

858

600

877

673

609

547

536

463

640

465

457

748

365

Non-cash interest expense

141

188

29

28

1

47

3

3

3

4

5

5

5

6

6

6

6

7

9

9

9

12

17

32

87

Accretion on debt securities available for sale, net

67

108

133

166

175

154

90

2

-9

36

-35

-50

-79

-83

-69

-39

-74

-

-

-

-

-

-

-

-

Depreciation and amortization expense

72

-

-

-

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability, purchase rights and warrant purchase rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,759

Depreciation

-

-

-

-

-

22

18

17

11

7

9

10

9

9

9

9

8

8

6

2

1

-

-

-

-

Change in assets and liabilities:
Prepaid expenses and other current assets

-429

858

-2,542

-1,488

3,626

-532

309

-273

647

-122

620

260

42

-31

-9

-23

-214

-109

340

89

-55

29

-66

259

1

Accounts payable

264

235

-2,125

-1,315

358

-391

2,640

-816

617

515

-277

67

419

-458

-89

245

-273

107

114

223

64

-141

103

213

-175

Accrued interest on convertible notes related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

2

Accrued expenses

-8,285

437

7,957

-1,588

-764

1,589

-413

2,343

-421

729

468

-481

-425

469

392

51

-153

570

178

21

-478

530

152

78

15

Net cash used in operating activities

-15,359

-11,226

-8,315

-12,810

-12,631

-7,968

-7,688

-6,245

-7,954

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-4,186

-3,909

-3,503

-3,253

-4,481

-3,005

-2,860

-1,601

-1,843

-1,606

-1,210

-894

-1,063

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment

-

0

0

4

4

14

47

61

139

13

0

0

11

0

0

2

9

0

54

30

1

-

-

-

-

Purchases of marketable securities

5,776

20,907

15,394

13,073

8,392

38,157

9,482

8,081

4,009

14,896

10,927

6,118

3,151

-

-

-

-

-

-

-

-

-

-

-

-

Sales of marketable securities

12,000

16,645

21,000

21,000

17,000

9,200

9,509

9,000

8,950

6,800

7,300

6,767

4,055

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

6,223

-4,285

5,675

7,922

9,164

-28,972

-21

856

4,801

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

891

1,319

566

-2,102

-9

-12,950

-54

-30

-1

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs

3,172

7,170

0

-86

807

67,642

1,070

9,031

4,093

-4

26,888

2

10,583

-

-

-

-

-

-14

19,480

9,039

-

-

-

-

Proceeds from exercise of stock options

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from employee stock purchase plan

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs paid in cash

-

0

-278

1

400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

3,252

8,333

14,844

-9

407

66,289

1,112

9,031

4,093

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET DECREASE IN CASH AND CASH EQUIVALENTS

-5,882

-

-

-

-3,059

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs not yet paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-

-

-

209

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

141

191

SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES:
Deferred offering costs paid in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

-

-

-

-

-

-

-

52

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

10,583

36

-102

12,814

-9

-14

-36

19,480

9,039

0

-176

10,284

-52

NET (DECREASE)/INCREASE IN CASH

-

-

-

-

-

-

-

3,642

940

-13,080

18,494

-4,693

7,287

-2,553

-3,039

7,458

-4,500

-15,969

-2,951

17,848

7,193

-1,614

-1,393

9,390

-1,116

Interest

-

-

-

-

-

-

-

-

-

-

-

-

20

-

-

-

-

18

18

19

18

19

26

28

22

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Helio Vision, Inc [Member]
Acquired in-process research and development

6,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in Helio asset acquisition

-

-22

69

0

562

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs of public offerings not yet paid

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets acquired

-

0

0

0

75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liabilities acquired

-

0

0

0

637

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of securities issued

-

81

0

0

4,862

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets acquired through operating leases

-

-

0

8

377

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

345

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-